,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1189,1,5,,48413480,5284371,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
1,1194,1,3,,48413480,5284371,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
2,1195,1,2,,48415816,5284371,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
3,1199,1,3,,48413480,5284371,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
4,1205,1,4,,48413480,5284371,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
5,1208,1,3,,48413480,5284371,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
6,7783,3,4,,103169342,5284371,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
7,8002,5,2,,103169342,5284371,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
8,18980,4,5,,103169342,5284371,Unspecified,,,,,Pharmacokinetic parameter Log D of compound; LogD at pH 7.4,Other,8893832.0,
9,19240,4,4,,103169342,5284371,Unspecified,,,,,Partition coefficient of Zwitterion (logD),Other,8893832.0,
10,19246,4,4,,103169342,5284371,Unspecified,,,,,Partition coefficient of cation (logD),Other,8893832.0,
11,19262,5,1,,103169342,5284371,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
12,19424,3,4,,103169342,5284371,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
13,22293,4,4,,103169342,5284371,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
14,23717,4,3,,103169342,5284371,Unspecified,,,,,Partition coefficient (logP),Other,2831361.0,
15,25846,3,3,,103169342,5284371,Unspecified,,,,,Pharmacokinetic parameter amine pKa of compound,Other,8893832.0,
16,26304,4,4,,103169342,5284371,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
17,26362,4,3,,103169342,5284371,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
18,29359,3,3,,103169342,5284371,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
19,29811,4,3,,103169342,5284371,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
20,54562,6,7,,103169342,5284371,Unspecified,117241.0,266684.0,1320.0,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D1 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
21,54564,6,7,,103169342,5284371,Unspecified,117242.0,25053.0,238.0,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D2 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
22,54565,6,7,,103169342,5284371,Unspecified,3915646.0,24303.0,4089.0,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D3 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
23,54566,6,7,,103169342,5284371,Unspecified,117244.0,,2216.0,IC50,Inhibition of MAMC O-dealkylation mediated by rat Cytochrome P450 2D4 expressed in Saccharomyces cerevisiae,Confirmatory,12502361.0,
24,54570,6,7,,103169342,5284371,Unspecified,84028191.0,1565.0,104.0,IC50,Inhibition of MAMC O-dealkylation mediated by human Cytochrome P450 2D6 expressed in human lymphoblastoid cell line,Confirmatory,12502361.0,
25,108541,6,2,,103169342,5284371,Inactive,,,,,Compound was administered subcutaneously and was evaluated for opioid antagonist activity (versus morphine) by tail-flick (TF) antagonism test; I denotes Inactive at 30 mg/kg,Other,6708055.0,
26,109795,3,3,,103169342,5284371,Active,,,,,General behavior in mice after oral administration (750 mg/kg) using acute toxicity assay; Convulsions,Other,8386248.0,
27,112942,6,2,,103169342,5284371,Unspecified,,,,,Analgesic activity in mice using p-phenylquinone test.,Other,8386248.0,
28,114491,6,2,,103169342,5284371,Unspecified,,,,,"Compound was administered subcutaneously and was evaluated for opioid agonist activity by antinociceptive hotplate (HP) assay in mice,",Other,6708055.0,
29,114495,6,2,,103169342,5284371,Unspecified,,,,,"Compound was administered subcutaneously and was evaluated for opioid agonist activity by antinociceptive p-phenylquinone-writhing (PPQ) assay in mice,",Other,6708055.0,
30,114498,6,2,,103169342,5284371,Unspecified,,,,,Compound was administered subcutaneously and was evaluated for opioid agonist activity by antinociceptive tail-flick (TF) assay in mice.,Other,6708055.0,
31,117605,3,3,,103169342,5284371,Unspecified,,,,,Percent mortality in mice after oral administration (750 mg/kg) using acute toxicity assay,Other,8386248.0,
32,125688,3,3,,103169342,5284371,Inactive,,,,,Antagonistic potency of the compound; not active,Other,1433169.0,
33,126331,7,2,,103169342,5284371,Unspecified,,,,,Analgesic activity in monkeys.,Other,1433169.0,
34,126652,3,3,,103169342,5284371,Active,,,,,Physical dependence capacity (PDC) of the compound; intermed physical dependence capacity,Other,1433169.0,
35,127137,3,3,,103169342,5284371,Active,,,,,Physical dependence capacity at abstinence suppressant dose; Intermediate,Other,7365738.0,
36,127831,7,2,,103169342,5284371,Unspecified,,,,,Narcotic agonist activity using acetic acid induced writhing in the mouse upon subcutaneous administration,Other,6864732.0,
37,128023,7,2,,103169342,5284371,Unspecified,,,,,Compound was tested for analgesia in mouse writhing assay by subcutaneous administration,Other,7192744.0,
38,128027,7,2,,103169342,5284371,Unspecified,,,,,Compound was tested for analgesic activity by writhing assay in mouse after subcutaneous administration,Other,6114178.0,
39,128214,7,2,,103169342,5284371,Unspecified,,,,,Narcotic agonistic activity in acetic acid mouse writhing assay after subcutaneous administration of the drug,Other,7310822.0,
40,128505,6,2,,103169342,5284371,Unspecified,,,,,Analgesic activity was determined by tail flick assay after subcutaneous administration in mice,Other,6292420.0,
41,128507,6,2,,103169342,5284371,Unspecified,,,,,Analgesic activity was determined by writhing test after subcutaneous administration in mice,Other,6292420.0,
42,129302,6,2,,103169342,5284371,Unspecified,,,,,Antinociceptive activity by measuring inhibition of acetylcholine writhing in mouse,Other,6681842.0,
43,131018,7,2,,103169342,5284371,Unspecified,,,,,"Analgesic agonist activity in acetic acid induced mouse writhing assay, subcutaneous administration",Other,6166748.0,
44,132133,7,2,,103169342,5284371,Unspecified,,,,,The effective dose was measured by using mouse writhing assay after the compound administered subcutaneously.,Other,6767032.0,
45,132480,10,1,,103169342,5284371,Unspecified,,,,,Analgesic activity in mouse,Other,7365738.0,
46,147865,7,1,,103169342,5284371,Active,,,15.0,IC50,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,Confirmatory,12502358.0,
47,148090,7,1,,103169342,5284371,Unspecified,,,9.3,IC50,In vitro binding affinity against cloned human Opioid receptor delta 1 expressed in HEK 293S cells,Confirmatory,12502358.0,
48,150244,12,1,,103169342,5284371,Active,,,10.0,IC50,Concentration required to inhibit [3H]naltrexone binding to Opioid receptors,Confirmatory,6292420.0,
49,150822,7,2,,103169342,5284371,Active,,,0.105,IC50,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,Confirmatory,12502358.0,
50,151006,3,7,,103169342,5284371,Unspecified,,,,,Selectivity of mu IC50 to that of delta IC50 was calculated,Other,12502358.0,
51,151584,4,7,,103169342,5284371,Unspecified,,,,,Binding constant for the agonist state was measured for its ability to displace [3H]naloxone from opioid mu 1 receptor buffered homogenate of rat brain membranes,Other,2831361.0,
52,151914,4,7,,103169342,5284371,Unspecified,,,,,Binding constant for the antagonist state was measured for its ability to displace [3H]naloxone from opioid mu 1 receptor buffered homogenate of rat brain membranes,Other,2831361.0,
53,173386,3,3,,103169342,5284371,Unspecified,,,,,Behavioral stimulant activity in rat by peroral administration; Inactive,Other,6681842.0,
54,178138,7,2,,103169342,5284371,Unspecified,,,,,Compound was tested for analgesic activity by tail-flick assay in rat after subcutaneous administration,Other,6114178.0,
55,178144,7,2,,103169342,5284371,Unspecified,,,,,Analgesic agonist activity in heat stimulus rat tail-flick assay on subcutaneous administration,Other,6166748.0,
56,178161,7,2,,103169342,5284371,Unspecified,,,,,Antagonist activity in rat tail flick assay by subcutaneous administration,Other,7192744.0,
57,178325,7,2,,103169342,5284371,Unspecified,,,,,Compound was tested for antinociceptive activity in heat stimulus rat tail flick assay after subcutaneous administration of the drug,Other,7310822.0,
58,178670,6,2,,103169342,5284371,Unspecified,,,,,Antinociceptive activity by measuring in flamed paw pressure threshold in rat,Other,6681842.0,
59,179385,4,5,,103169342,5284371,Active,,,2.6,IC50,Concentration of drug required to inhibit the stereospecific binding of [3H]-naloxone (5 nM) to homogenates of rat brain minus cerebellum in the absence of 100 mM NaCl,Confirmatory,6325691.0,
60,179386,4,6,,103169342,5284371,Active,,,22.0,IC50,Concentration of drug required to inhibit the stereospecific binding of [3H]naloxone (5 nM) to homogenates of rat brain minus cerebellum in the presence of 100 mM NaCl,Confirmatory,6325691.0,
61,180157,7,2,,103169342,5284371,Unspecified,,,,,Effective dose was measured by using rat tail flick assay after subcutaneous administration,Other,6767032.0,
62,183317,3,3,,103169342,5284371,Unspecified,,,,,Anti-inflammatory effect expressed as % inhibition at 50 mg/kg in acute carrageenan paw edema test in rats,Other,8386248.0,
63,205268,4,7,,103169342,5284371,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
64,228903,6,2,,103169342,5284371,Unspecified,,,,,Effective dose required to produce analgesic activity in the adjuvant arthritis hyperalgesia assay by oral administration,Other,12540239.0,
65,228904,6,2,,103169342,5284371,Unspecified,,,,,Effective dose required to produce analgesic activity in the phalanges algesia assay by oral administration,Other,12540239.0,
66,228905,6,2,,103169342,5284371,Unspecified,,,,,Effective dose required to produce analgesic activity in the trypsin hyperalgesia assay by oral administration,Other,12540239.0,
67,233518,4,3,,103169342,5284371,Inactive,,,,,Antagonistic potency was evaluated as analgesic activity in presence of nalorphine; No,Other,7365738.0,
68,234027,3,5,,103169342,5284371,Unspecified,,,,,The sodium index is the ratio of the IC50 value for the inhibition of [3H]naloxone binding to homogenates of rat brain minus cerebellum in presence of 100 mM of NaCl.,Other,6325691.0,
69,243151,7,2,,103169342,5284371,Unspecified,,,301.995,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
70,311367,3,6,,103169342,5284371,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
71,311524,4,3,,103169342,5284371,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
72,320419,8,1,,103169342,5284371,Active,,,34.7,EC50,Displacement of 3.0 nM [3H]etorphine from opioid receptor in rat cerebrum,Confirmatory,17962026.0,
73,327875,3,10,,103169342,5284371,Unspecified,2851402.0,4988.0,,,Activation of human mu opioid receptor expressed in HEK293a cells co-expressing YFP-labelled alphai1 and CFP-labelled beta1gamma2 Gi subunits assessed as decrease in fluorescence resonance energy transfer signal at 100 uM relative to morphine,Other,17616524.0,
74,327877,9,5,,103169342,5284371,Active,2851402.0,4988.0,6.1,EC50,Activation of human mu opioid receptor expressed in HEK293a cells co-expressing YFP-labelled alphai1 and CFP-labelled beta1gamma2 Gi subunits assessed as Gi protein activation by fluorescence resonance energy transfer,Confirmatory,17616524.0,
75,327878,9,5,,103169342,5284371,Active,2851402.0,4988.0,6.3,Ki,Displacement of [3H]naloxone from human mu poioid receptor expressed in HEK293 cells,Confirmatory,17616524.0,
76,330418,3,11,,103169342,5284371,Active,238054374.0,5243.0,,,Effect on human recombinant Pgp-mediated ATP consumption assessed as increase in ATPase activity at 200 uM by Pgp-Glo assay,Other,18311899.0,
77,330420,7,2,,103169342,5284371,Active,,,0.727,Ki,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,Confirmatory,18311899.0,
78,330421,7,1,,103169342,5284371,Unspecified,,,52.207,Ki,Displacement of [3H]diprenorphine from recombinant delta opioid receptor expressed in C6 cells,Confirmatory,18311899.0,
79,330422,7,1,,103169342,5284371,Active,,,25.410999999999998,Ki,Displacement of [3H]diprenorphine from recombinant kappa opioid receptor expressed in CHO cells,Confirmatory,18311899.0,
80,330423,3,3,,103169342,5284371,Unspecified,,,,,Selectivity for recombinant mu opioid receptor over recombinant delta opioid receptor,Other,18311899.0,
81,330424,3,3,,103169342,5284371,Unspecified,,,,,Selectivity for recombinant mu opioid receptor over recombinant kappa opioid receptor,Other,18311899.0,
82,352476,6,2,,103169342,5284371,Unspecified,,,,,Antitussive activity in po dosed guinea pig GPPV model assessed as reduction of capsaicin-induced coughing after 2 hrs administered 15 mins before capsaicin challenge,Other,19332374.0,
83,352652,7,2,,103169342,5284371,Unspecified,,,,,Antitussive activity against capsaicin-induced cough in po dosed Hartley guinea pig model after 2 hrs,Other,19339177.0,
84,352653,7,2,,103169342,5284371,Inconclusive,,,,,Anxiolytic activity in po dosed CD rats assessed as suppression of conditioned paw licking administered twice per day for 14 days measured after 2 hrs of last dose,Other,19339177.0,
85,352654,7,2,,103169342,5284371,Inconclusive,,,,,Anxiolytic activity in Dunkin-Hartley guinea pig pup assessed as reduction in number of vocalization produced due to separation measured after 2 hrs,Other,19339177.0,
86,377382,3,3,,103169342,5284371,Unspecified,,,,,"Antitussive activity in ammonia liquor-induced mouse assessed as number of cough times at 10 mg/kg, po daily for 3 consecutive days administered before ammonia liquor induction measured for 3 mins",Other,15730259.0,
87,386623,4,8,,103169342,5284371,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
88,409954,4,9,,103169342,5284371,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
89,409956,4,9,,103169342,5284371,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
90,425652,7,2,,103169342,5284371,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
91,425653,7,2,,103169342,5284371,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
92,427367,6,2,,103169342,5284371,Unspecified,,,,,Antitussive activity against po dosed capsaicin-induced guinea pig cough model administered 15 mins before capsaicin challenge measured after 2 hrs,Other,19678644.0,
93,427370,3,3,,103169342,5284371,Inconclusive,,,,,"Anxiolytic-like activity in Dunkin-Hartley guinea pig assessed as reduction in number of separation-induced vocalizations at 0.3 mg/kg, po after 2 hrs by guinea pig pup vocalization assay",Other,19678644.0,
94,427372,6,2,,103169342,5284371,Inconclusive,,,,,Anxiolytic-like activity in po dosed 20 hrs water-deprived CD rat after 2 hrs by conditioned lick suppression assay,Other,19678644.0,
95,467611,3,6,,103169342,5284371,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
96,467612,3,6,,103169342,5284371,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
97,467613,5,3,,103169342,5284371,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
98,496817,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
99,496818,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
100,496819,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
101,496820,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
102,496821,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
103,496823,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
104,496824,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
105,496825,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
106,496826,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
107,496827,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
108,496828,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
109,496829,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
110,496830,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
111,496831,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
112,496832,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
113,497005,4,2,,103169342,5284371,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
114,540209,4,3,,103169342,5284371,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
115,540210,4,3,,103169342,5284371,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
116,540211,2,5,,103169342,5284371,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
117,540212,4,3,,103169342,5284371,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
118,540213,4,3,,103169342,5284371,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
119,567091,2,6,,103169342,5284371,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
120,588211,2,3,,103169342,5284371,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
121,588212,2,3,,103169342,5284371,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
122,588213,2,3,,103169342,5284371,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
123,589038,1,10,,103169342,5284371,Unspecified,84028191.0,1565.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP2D6",Other,,
124,589077,1,10,,103169342,5284371,Unspecified,6175083.0,7363.0,,,Substrate of human UDP-glucuronosyltransferase UGT2B4,Other,,
125,604020,1,4,,103169342,5284371,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
126,604021,3,1,,103169342,5284371,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
127,604022,1,4,,103169342,5284371,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
128,604023,1,3,,103169342,5284371,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
129,604024,1,3,,103169342,5284371,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
130,604025,1,4,,103169342,5284371,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
131,604026,1,4,,103169342,5284371,Unspecified,,,,,Unbound CSF to plasma concentration ratio in human,Other,19764786.0,
132,624607,1,9,,103169342,5284371,Unspecified,549152.0,54659.0,,,Specific activity of expressed human recombinant UGT1A3,Other,10836148.0,
133,624608,3,2,,103169342,5284371,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
134,624611,1,9,,103169342,5284371,Unspecified,29839637.0,54576.0,,,Specific activity of expressed human recombinant UGT1A8,Other,10836148.0,
135,624613,1,9,,103169342,5284371,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
136,624616,1,8,,103169342,5284371,Unspecified,332278237.0,7366.0,,,Specific activity of expressed human recombinant UGT2B15,Other,10836148.0,
137,624620,1,8,,103169342,5284371,Unspecified,136727.0,7364.0,,,Specific activity of expressed human recombinant UGT2B7H,Other,10836148.0,
138,624621,1,8,,103169342,5284371,Unspecified,136727.0,7364.0,,,Specific activity of expressed human recombinant UGT2B7Y,Other,10836148.0,
139,624640,3,7,,103169342,5284371,Unspecified,136727.0,7364.0,1800.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT2B7,Confirmatory,15781124.0,
140,651631,4,1,,144207280,5284371,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
141,651632,4,1,,144207280,5284371,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
142,651633,4,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
143,651634,4,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
144,720516,2,1,,144207280,5284371,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
145,720552,2,1,,144207280,5284371,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
146,720634,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
147,720635,2,1,,144207280,5284371,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
148,720637,2,1,,144207280,5284371,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
149,720674,2,2,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
150,720675,2,2,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
151,720678,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
152,720679,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
153,720680,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
154,720681,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
155,720682,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
156,720683,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
157,720684,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
158,720685,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
159,720686,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
160,720687,2,2,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
161,720691,4,1,,144207280,5284371,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
162,720692,3,1,,144207280,5284371,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
163,720693,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
164,720719,2,1,,144207280,5284371,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
165,720725,2,1,,144207280,5284371,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
166,743012,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
167,743014,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
168,743015,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
169,743033,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
170,743035,2,1,,144207280,5284371,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
171,743036,2,1,,144207280,5284371,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
172,743040,3,1,,144207280,5284371,Active,124375976.0,367.0,61.4415,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
173,743041,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
174,743042,3,1,,144207280,5284371,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
175,743053,2,1,,144207280,5284371,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
176,743054,2,1,,144207280,5284371,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
177,743063,2,1,,144207280,5284371,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
178,743064,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
179,743065,3,1,,144207280,5284371,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
180,743066,3,1,,144207280,5284371,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
181,743067,2,1,,144207280,5284371,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
182,743069,2,1,,144207280,5284371,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
183,743074,2,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
184,743075,2,1,,144207280,5284371,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
185,743077,2,1,,144207280,5284371,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
186,743078,2,1,,144207280,5284371,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
187,743079,3,1,,144207280,5284371,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
188,743080,3,1,,144207280,5284371,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
189,743081,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
190,743083,3,1,,144207280,5284371,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
191,743084,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
192,743085,3,1,,144207280,5284371,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
193,743086,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
194,743091,2,1,,144207280,5284371,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
195,743094,3,1,,144207280,5284371,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
196,743122,2,1,,144207280,5284371,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
197,743139,2,1,,144207280,5284371,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
198,743140,2,1,,144207280,5284371,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
199,743191,3,1,,144207280,5284371,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
200,743194,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
201,743199,2,1,,144207280,5284371,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
202,743202,4,1,,144207280,5284371,Inconclusive,20149576.0,4780.0,30.7937,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
203,743203,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
204,743209,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
205,743210,4,1,,144207280,5284371,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
206,743211,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
207,743212,3,1,,144207280,5284371,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
208,743213,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
209,743215,3,1,,144207280,5284371,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
210,743217,3,1,,144207280,5284371,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
211,743218,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
212,743219,3,1,,144207280,5284371,Active,20149576.0,4780.0,28.5186,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
213,743220,3,1,,144207280,5284371,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
214,743221,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
215,743222,3,1,,144207280,5284371,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
216,743223,3,1,,144207280,5284371,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
217,743224,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
218,743225,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
219,743226,2,1,,144207280,5284371,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
220,743227,2,1,,144207280,5284371,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
221,743228,3,1,,144207280,5284371,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
222,743239,2,1,,144207280,5284371,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
223,743240,2,1,,144207280,5284371,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
224,743241,2,1,,144207280,5284371,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
225,743242,2,1,,144207280,5284371,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
226,754479,1,1,,103169342,5284371,Unspecified,,,,,"Inhibition of gastrointestinal transit of charcoal meal in rat at 55.2 mg/kg, po",Other,23517479.0,
227,781328,1,2,,103169342,5284371,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
228,1057811,1,1,,103169342,5284371,Active,,,20.91,IC50,Inhibition of UDP-glucuronosyltransferase in Sprague-Dawley rat hepatocytes assessed as morphine conversion to M3G incubated for 72 hrs prior to substrate addition measured after 2 hrs by HPLC analysis,Confirmatory,24183585.0,
229,1057812,1,2,,103169342,5284371,Inactive,,,,,Competitive inhibition of UDP-glucuronosyltransferase in Sprague-Dawley rat liver microsomes assessed as morphine conversion to M3G up to 5 uM by Lineweaver-Burk plot analysis,Other,24183585.0,
230,1057813,1,2,,103169342,5284371,Inactive,,,,,Inhibition of UDP-glucuronosyltransferase in Sprague-Dawley rat liver microsomes assessed as morphine conversion to M6G after 30 mins by HPLC analysis,Other,24183585.0,
231,1057815,1,2,,103169342,5284371,Unspecified,,,,IC50,Inhibition of UDP-glucuronosyltransferase in Sprague-Dawley rat liver microsomes assessed as morphine conversion to M3G after 30 mins by HPLC analysis,Confirmatory,24183585.0,
232,1057816,1,2,,103169342,5284371,Unspecified,,,,,Clearance in Sprague-Dawley rat liver microsomes at 50 uM,Other,24183585.0,
233,1057817,1,2,,103169342,5284371,Unspecified,,,,,Clearance in Sprague-Dawley rat liver microsomes at 5 uM,Other,24183585.0,
234,1057818,1,2,,103169342,5284371,Unspecified,,,,,Clearance in Sprague-Dawley rat liver microsomes at 10 uM,Other,24183585.0,
235,1057819,1,2,,103169342,5284371,Unspecified,,,,,Clearance in Sprague-Dawley rat liver microsomes at 2.5 uM,Other,24183585.0,
236,1057820,1,2,,103169342,5284371,Unspecified,,,,,Clearance in Sprague-Dawley rat liver microsomes at 1 uM,Other,24183585.0,
237,1057821,1,2,,103169342,5284371,Unspecified,,,,Km,Activity at UDP-glucuronosyltransferase in Sprague-Dawley rat liver microsomes assessed as morphine conversion to M3G at 50 uM by Michaelis-Menten plot analysis,Confirmatory,24183585.0,
238,1057822,1,2,,103169342,5284371,Unspecified,,,,Km,Activity at UDP-glucuronosyltransferase in Sprague-Dawley rat liver microsomes assessed as morphine conversion to M3G at 10 uM by Michaelis-Menten plot analysis,Confirmatory,24183585.0,
239,1057823,1,2,,103169342,5284371,Unspecified,,,,Km,Activity at UDP-glucuronosyltransferase in Sprague-Dawley rat liver microsomes assessed as morphine conversion to M3G at 5 uM by Michaelis-Menten plot analysis,Confirmatory,24183585.0,
240,1057824,1,2,,103169342,5284371,Unspecified,,,,Km,Activity at UDP-glucuronosyltransferase in Sprague-Dawley rat liver microsomes assessed as morphine conversion to M3G at 2.5 uM by Michaelis-Menten plot analysis,Confirmatory,24183585.0,
241,1057825,1,2,,103169342,5284371,Unspecified,,,,Km,Activity at UDP-glucuronosyltransferase in Sprague-Dawley rat liver microsomes assessed as morphine conversion to M3G at 1 uM by Michaelis-Menten plot analysis,Confirmatory,24183585.0,
242,1079931,1,1,,103169342,5284371,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
243,1079932,1,1,,103169342,5284371,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
244,1079933,1,1,,103169342,5284371,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
245,1079934,1,1,,103169342,5284371,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
246,1079935,1,1,,103169342,5284371,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
247,1079936,1,1,,103169342,5284371,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
248,1079937,1,1,,103169342,5284371,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
249,1079938,1,1,,103169342,5284371,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
250,1079939,1,1,,103169342,5284371,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
251,1079940,1,1,,103169342,5284371,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
252,1079941,1,1,,103169342,5284371,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
253,1079942,1,1,,103169342,5284371,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
254,1079943,1,1,,103169342,5284371,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
255,1079944,1,1,,103169342,5284371,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
256,1079945,1,1,,103169342,5284371,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
257,1079946,1,1,,103169342,5284371,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
258,1079947,1,1,,103169342,5284371,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
259,1079948,1,1,,103169342,5284371,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
260,1079949,1,1,,103169342,5284371,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
261,1084890,1,2,,103169342,5284371,Active,,,,,"Antitussive activity against citric acid-induced cough in Cavia porcellus albino (guinea pig) model assessed as increase in cough latency at 10 mg/kg, ip administered 30 min before aersol of citric acid for 10 min",Other,,
262,1084891,1,2,,103169342,5284371,Active,,,,,"Antitussive activity against citric acid-induced cough in Cavia porcellus albino (guinea pig) model assessed as decrease in cough frequency per 10 min at 10 mg/kg, ip administered 30 min before aersol of citric acid for 10 min",Other,,
263,1097336,1,3,,103169342,5284371,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
264,1124317,1,1,,103169342,5284371,Unspecified,,,,,Analgesic activity in sc dosed mouse by eddy's hot-plate method,Other,430484.0,
265,1133599,1,1,,103169342,5284371,Unspecified,,,,,"Antitussive activity in Dunkin-Hartley guinea pig assessed as inhibition of electrically-stimulated vagus nerve-induced cough at 100 mg/kg, po administered compound prior to electrical stimulation of vagus nerve measured at 20 to 40 mins relative to control",Other,836490.0,
266,1133600,1,1,,103169342,5284371,Unspecified,,,,,Antitussive activity in po dosed Dunkin-Hartley guinea pig assessed as inhibition of electrically-stimulated vagus nerve-induced cough administered compound prior to electrical stimulation of vagus nerve measured at 20 to 40 mins,Other,836490.0,
267,1135667,1,1,,103169342,5284371,Unspecified,,,,,Analgesic activity in sc dosed mouse by hot-plate method,Other,209187.0,
268,1135668,1,1,,103169342,5284371,Unspecified,,,,,Analgesic activity in sc dosed mouse by Nilsen method,Other,209187.0,
269,1136225,1,1,,103169342,5284371,Unspecified,,,,,"Analgesic activity in Sprague-Dawley rat brewer's yeast treated foot assessed as response threshold at 8 to 16 mg/kg, po",Other,309950.0,
270,1136228,1,1,,103169342,5284371,Unspecified,,,,,"Analgesic activity in Sprague-Dawley rat normal foot assessed as response threshold at 16 to 32 mg/kg, po",Other,309950.0,
271,1137105,1,1,,103169342,5284371,Unspecified,,,,,Analgesic activity in sc dosed mouse by hot plate method,Other,408488.0,
272,1137110,1,1,,103169342,5284371,Unspecified,,,,,Analgesic activity in sc dosed mouse by Nilsen method,Other,408488.0,
273,1137221,1,1,,103169342,5284371,Unspecified,,,,,Analgesic activity in mouse by Eddy hot-plate method,Other,413922.0,
274,1146145,1,1,,103169342,5284371,Unspecified,,,,,Analgesic activity in sc dosed mouse by hot-plate assay,Other,199728.0,
275,1146147,1,1,,103169342,5284371,Unspecified,,,,,Analgesic activity in sc dosed mouse by Nilsen method,Other,199728.0,
276,1149090,1,1,,103169342,5284371,Unspecified,,,,,Analgesic activity in po dosed mouse by Nilsen assay,Other,815550.0,
277,1159509,1,1,,144207280,5284371,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
278,1159515,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
279,1159516,1,1,,144207280,5284371,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
280,1159517,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
281,1159518,1,1,,144207280,5284371,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
282,1159519,1,1,,144207280,5284371,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
283,1159520,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
284,1159521,1,1,,144207280,5284371,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
285,1159523,1,1,,144207280,5284371,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
286,1159525,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
287,1159526,1,1,,144207280,5284371,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
288,1159527,1,1,,144207280,5284371,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
289,1159528,1,1,,144207280,5284371,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
290,1159529,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
291,1159531,1,1,,144207280,5284371,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
292,1159551,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
293,1159552,1,1,,144207280,5284371,Inconclusive,325495463.0,5914.0,48.8047,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
294,1159553,2,1,,144207280,5284371,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
295,1159555,1,1,,144207280,5284371,Active,325495463.0,5914.0,24.4603,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
296,1159620,1,1,,103169342,5284371,Active,,,,,Summary of drug indications.,Other,,
297,1209581,1,2,,103169342,5284371,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
298,1209582,1,1,,103169342,5284371,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
299,1209583,1,1,,103169342,5284371,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
300,1209593,1,1,,103169342,5284371,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
301,1222793,1,1,,103169342,5284371,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
302,1224834,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
303,1224835,1,1,,144207280,5284371,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
304,1224836,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
305,1224837,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
306,1224838,1,1,,144207280,5284371,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
307,1224839,1,1,,144207280,5284371,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
308,1224840,3,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
309,1224841,3,1,,144207280,5284371,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
310,1224842,3,1,,144207280,5284371,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
311,1224843,1,1,,144207280,5284371,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
312,1224844,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
313,1224845,1,1,,144207280,5284371,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
314,1224846,1,1,,144207280,5284371,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
315,1224847,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
316,1224848,3,1,,144207280,5284371,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
317,1224849,3,1,,144207280,5284371,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
318,1224867,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
319,1224868,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
320,1224869,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
321,1224870,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
322,1224871,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
323,1224872,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
324,1224873,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
325,1224874,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
326,1224875,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
327,1224876,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
328,1224877,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
329,1224878,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
330,1224879,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
331,1224880,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
332,1224881,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
333,1224882,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
334,1224883,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
335,1224884,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
336,1224885,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
337,1224886,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
338,1224887,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
339,1224888,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
340,1224889,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
341,1224890,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
342,1224892,1,1,,144207280,5284371,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
343,1224893,1,1,,144207280,5284371,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
344,1224894,1,1,,144207280,5284371,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
345,1224895,1,1,,144207280,5284371,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
346,1224896,1,1,,144207280,5284371,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
347,1259241,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
348,1259242,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
349,1259243,1,1,,144207280,5284371,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
350,1259244,1,1,,144207280,5284371,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
351,1259247,1,1,,144207280,5284371,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
352,1259248,1,1,,144207280,5284371,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
353,1259364,1,1,,144207280,5284371,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
354,1259365,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
355,1259366,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
356,1259367,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
357,1259368,1,1,,144207280,5284371,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
358,1259369,1,1,,144207280,5284371,Inconclusive,109731339.0,2737.0,17.3166,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
359,1259377,1,1,,144207280,5284371,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
360,1259378,1,1,,144207280,5284371,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
361,1259379,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
362,1259380,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
363,1259381,1,1,,144207280,5284371,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
364,1259382,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
365,1259383,1,1,,144207280,5284371,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
366,1259384,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
367,1259385,1,1,,144207280,5284371,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
368,1259386,1,1,,144207280,5284371,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
369,1259387,1,1,,144207280,5284371,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
370,1259388,1,1,,144207280,5284371,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
371,1259390,1,1,,144207280,5284371,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
372,1259391,1,1,,144207280,5284371,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
373,1259392,1,1,,144207280,5284371,Active,109731339.0,2737.0,17.3166,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
374,1259393,1,1,,144207280,5284371,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
375,1259394,1,1,,144207280,5284371,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
376,1259395,1,1,,144207280,5284371,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
377,1259396,1,1,,144207280,5284371,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
378,1259401,1,1,,144207280,5284371,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
379,1259402,1,1,,144207280,5284371,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
380,1259403,1,1,,144207280,5284371,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
381,1259404,1,1,,144207280,5284371,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
382,1259411,1,1,,363905505,5284371,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
